KYNTRA BIO (KYNB) CFO has 52 shares withheld to cover RSU tax

Rhea-AI Filing Summary

KYNTRA BIO, INC. Chief Financial Officer David DeLucia reported a routine tax-related share disposition tied to equity compensation. On the reported date, 52 shares of common stock were withheld by the company at a value of $6.71 per share to satisfy a tax obligation that arose when restricted stock units vested. Following this withholding, DeLucia holds 4,377 shares of KYNTRA BIO common stock directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DeLucia David

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	52	$6.71	$348.92

Holdings After Transaction: Common Stock — 4,377 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Tax withholding shares: 52 shares Withholding share value: $6.71 per share Post-transaction holdings: 4,377 shares +1 more

4 metrics

Tax withholding shares 52 shares Shares withheld to satisfy tax obligation on RSU vesting

Withholding share value $6.71 per share Value used for tax withholding on 52 shares

Post-transaction holdings 4,377 shares Common stock directly held after tax withholding

Tax-withholding transactions 1 transaction, 52 shares Summary of tax-withholding activity in this Form 4

Key Terms

restricted stock units, tax obligation, Form 4, withheld by the issuer

4 terms

restricted stock units financial

"upon the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligation financial

"withheld by the issuer to satisfy a tax obligation"

Form 4 regulatory

"This Form 4 shows a tax-related disposition"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

withheld by the issuer financial

"Represents shares withheld by the issuer to satisfy a tax obligation"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeLucia David

(Last) (First) (Middle)

C/O KYNTRA BIO INC.

350 BAY STREET, SUITE 100 # 6009

(Street)

SAN FRANCISCO CALIFORNIA 94133

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
KYNTRA BIO, INC. [ KYNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/06/2026		F		52(1)	D	$6.71	4,377	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock units.

	/s/ John Alden, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did KYNTRA BIO (KYNB) disclose for CFO David DeLucia?

KYNTRA BIO reported that CFO David DeLucia had 52 common shares withheld to cover taxes on vesting restricted stock units. This Form 4 shows a tax-related disposition, not an open-market purchase or sale.

How many KYNTRA BIO (KYNB) shares were involved in the latest Form 4?

The filing shows 52 shares of KYNTRA BIO common stock were withheld. These shares were used to satisfy a tax obligation triggered by the vesting of restricted stock units, rather than being traded in the open market.

At what price were the KYNTRA BIO (KYNB) shares valued for the tax withholding?

The 52 withheld shares were valued at $6.71 per share. This value is used for calculating the tax obligation associated with the vesting of restricted stock units and does not represent a traditional market sale transaction.

How many KYNTRA BIO (KYNB) shares does CFO David DeLucia hold after this transaction?

After the tax withholding transaction, CFO David DeLucia directly holds 4,377 shares of KYNTRA BIO common stock. This figure reflects his position after 52 shares were withheld to pay taxes on vested restricted stock units.

Was the KYNTRA BIO (KYNB) insider transaction a market sale of shares?

No, the transaction was not a market sale. The 52 shares were withheld by the issuer to satisfy a tax obligation from restricted stock units vesting, which is a common, mechanical step in stock-based compensation.